QUICK LINKS
MAIN MENU
CONNECT WITH US

Clinical Trial Details

Title
Gilead GS-US-380-1474: A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/ Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children
Study Description

To test the safety, effectiveness, and pharmacokinetics of a new HIV medication, GS-9883.

Participants will receive the new medication for 48 weeks. During that time, participants will have clinic visits, physical exams, and blood tests at Screening, Day 1, Weeks 1, 2, 4, 8, 12, 16, 24, 36, 48, and a 30 day follow-up visit.

Investigators

Sub Investigator
Nizar F. Maraqa, M.D.
Pediatrics

Sub Investigator
Ayesha Mirza, M.D.
Pediatrics

Resources

News & Announcements

Upcoming Events

Jun 2

The Anatomy of Abstracts and Manuscripts

From 12:00 PM until 1:00 PM